![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supporting Information]](https://edoc.mdc-berlin.de/style/images/fileicons/application_msword.png) |
MS Word (Supporting Information)
24kB |
| Item Type: | Article |
|---|---|
| Title: | Analysis of soluble interleukin-2 receptor as a prognostic biomarker in NMOSD and MOGAD |
| Creators Name: | Klyscz, Philipp, Otto, Carolin, Ruprecht, Klemens, Asseyer, Susanna, Tiedt, Hannes Ole, Meisel, Christian, Bellmann-Strobl, Judith, Paul, Friedemann and Schindler, Patrick |
| Abstract: | OBJECTIVE: Soluble interleukin-2 receptor (sIL-2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) pathogenesis. However, sIL-2R has so far not been evaluated in these conditions. Here, we compared sIL-2R levels in serum and cerebrospinal fluid (CSF) of patients with aquaporin-4-IgG-seropositive and seronegative (AQP4-IgG+/-) NMOSD, MOGAD, and noninflammatory neurologic disorders (NINDs), and assessed the prognostic value of sIL-2R for future attacks. METHODS: Retrospective analysis of real-world data of patients treated at Charité-Universitätsmedizin Berlin was conducted (45 MOGAD, 14 AQP4-IgG+NMOSD, 10 AQP4-IgG-NMOSD, 69 NINDs) between 2010 and 2024. Mean (SD) follow-up time was 40 (35) months. sIL-2R differences were assessed by linear mixed models. Cox regression analysis was performed to investigate the predictive value for subsequent attacks. RESULTS: Serum sIL-2R was higher in AQP4-IgG+NMOSD (estimated marginal mean [EMM] 802 IU/mL) and MOGAD (569 IU/mL) compared to NINDs (404 IU/mL). In patients with a first manifestation of MOGAD, but not NMOSD, serum sIL-2R (HR = 9.07 [95% CI 1.37-60.01]) and CSF sIL-2R (HR = 3.27 [95% CI 0.61-17.45]) levels were predictive for subsequent attacks. INTERPRETATION: Serum sIL-2R is elevated in AQP4-IgG+NMOSD and MOGAD and may be a prognostic biomarker for a relapsing disease course in MOGAD. |
| Keywords: | Biomarker, MOGAD, NMOSD, Soluble Interleukin-2 Receptor |
| Source: | Annals of Clinical and Translational Neurology |
| ISSN: | 2328-9503 |
| Publisher: | Wiley |
| Date: | 5 September 2025 |
| Official Publication: | https://doi.org/10.1002/acn3.70186 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
